Mostrar el registro sencillo del ítem

dc.contributor.authorTorrente López, Anabel 
dc.contributor.authorHermosilla Fernández, Jesús 
dc.contributor.authorSalmerón García, Antonio
dc.contributor.authorCabeza, José
dc.contributor.authorNavas Iglesias, Natalia Africa 
dc.date.accessioned2022-05-17T06:56:57Z
dc.date.available2022-05-17T06:56:57Z
dc.date.issued2022-03-23
dc.identifier.citationTorrente-López, A... [et al.]. Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress. Pharmaceutics 2022, 14, 692. [https://doi.org/10.3390/pharmaceutics14040692]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/74853
dc.descriptionThis study was partially funded by Project P20-01029 (I+D+i-Junta de Andalucia, Spain) and by Project B-FQM-308-UGR20 (Universidad de Granada, Proyectos I+D+i del Programa Operativo FEDER Andalucia 2020) which means that it was also partially supported by European Regional Development Funds.es_ES
dc.description.abstractNivolumab, formulated in the medicine Opdivo (R) (10 mg/mL), is a therapeutic monoclonal antibody (mAb) used in the treatment of different types of cancer. Currently, there is insufficient knowledge about the behaviour of this protein with regards to the risk associated with its routine handling or unintentional mishandling, or when subjected to stress conditions in hospitals. These conditions can be simulated in forced degradation studies, which provide an in-depth understanding of the biophysical and biochemical properties of mAbs. In this study, we carried out a physicochemical and functional characterisation of nivolumab, which was subjected to various stress conditions: heat, freeze/thaw cycles, agitation, light exposure and high hypertonic solution. We used a wide range of analytical techniques: Far-UV CD, IT-FS, DLS, SE/UHPLC(UV)-[Native]MS, and ELISA. The results show that exposure to light was the stress test with the greatest impact on the samples, revelling the formation of non-natural dimers and a different isoform profile. In addition, nivolumab (Opdivo (R)) demonstrated stability up to 60 degrees C (1 h). As regards functionality all the nivolumab (Opdivo (R)) stressed samples were found to be stable except for those subjected to light and agitation, and to a lesser extent, those subjected to FTC 5 and NaCl stresses.es_ES
dc.description.sponsorshipI+D+i-Junta de Andalucia, Spain P20-01029es_ES
dc.description.sponsorshipEuropean Commission B-FQM-308-UGR20es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectNivolumabes_ES
dc.subjectComprehensive analytical characterisationes_ES
dc.subjectForced degradationes_ES
dc.subjectUHPLC-MSes_ES
dc.subjectIsoform profilees_ES
dc.titleComprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stresses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/pharmaceutics14040692
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España